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doi:10.1016/j.ejvs.2011.04.006Abstract Objective: Patient and device selection are important for the success of carotid
artery stenting (CAS). We hypothesize that distal protection filter (DPF) design characteristics
that minimize blood flow resistance and maximize capture efficiency are associated with the
absence of transient ischemic attack (TIA), stroke and neurologic-related death after 30 days.
Methods: Records from 208 patients were reviewed retrospectively. Filter design characteris-
tics were quantified previously in our laboratory. The association between risk factors and
design characteristics with 30-day outcome was quantified using univariate analysis.
Results: The 30-day all-cause stroke and death rate was 8.7% (asymptomatic: 7.7%, symptom-
atic: 10.6%). Five DPFs were used in the study: Accunet (41.3%), Angioguard (33.2%), FilterWire
(24%), Emboshield (1%), and Spider (.5%). Diabetes (PZ .04) and prior carotid endarterectomy
(CEA, P Z .03) were associated with adverse outcome. Prior stroke (P Z .01) and prior CEA
(P Z .04) were significant for peri-procedural stroke. Design characteristics such as capture
efficiency were associated with favorable outcomes.
Conclusions: Patients with prior CEA or stroke are more likely to have unfavorable CAS
outcomes after 30 days. Filters with high capture efficiency may yield the best clinical results.
Analysis of the effect of design characteristics on CAS outcome should aid the design of future
devices.
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Clinical Variables, DPFs, and CAS 283Introduction
The surgical (carotid endarterectomy [CEA]) and endovas-
cular (carotid artery stenting [CAS]) treatments of carotid
artery occlusive disease are perceived to be complementary
procedures. Thus, patient selection is considered crucial to
the success of either form of treatment. It is widely accepted
that the use of cerebral protection devices (CPDs) is crucial to
the success of CAS.1 In particular, distal protection filters
(DPFs) arewidely used due to their ability ofmaintaining peri-
procedural blood flow. The selection of stents and cerebral
protection devices is also important for favorable outcome.2
Previous studies have examined the effect risk fact-
ors,310 blood flow (measurements using hypotension11 or
hemodynamic instability12), lesion characteristics,13 and
plaque composition (determined by amount of debris
trapped by the CPD,14 by histology,15 and by intravascular
ultrasound16) have on CAS patient outcome. Few studies
have incorporated device design characteristics in their
analysis other than stent cell type.2,17e21 Roffi,22 Hart,2 and
Iyer23 examined the effects of DPFs on peri-procedural flow
impairment, concentricity of DPFs on 30-day patient
outcomes, and type of CPD on 30-day patient outcomes,
respectively. These studies classified DPFs based on
eccentricity, but did not evaluate the specific design
features, concluding that further analysis of device design
characteristics is necessary.2 Our laboratory has previously
quantified key DPF design characteristics and studied their
effect on filter capture efficiency and flow resistance using
a bench-top testing apparatus.24 We hypothesize that DPF
design characteristics that minimize resistance to blood
flow and maximize emboli capture efficiency will be nega-
tively associated with adverse 30-day patient outcome.
Therefore, the goal of this investigation is to quantify the
association between clinical and DPF design characteris-
tics, and assess their respective relationship to adverse CAS
outcome (i.e., the occurrence of transient ischemic attack
[TIA], stroke, or neurologic-related death) within 30 days of
the procedure.
Methods
A retrospective review of medical records of CAS patients
was pursued following approval of an Institutional Review
Board protocol waivering HIPAA authorization by the local
ethics committees. Patient information was de-identified
to exclude the patient’s name, social security number,
address and telephone number, medical record number, or
any other information that could be used to identify the
patient. The records were stored electronically, and were
locked and secured. The clinical and 30-day outcome data
was recorded for 208 patients treated non-consecutively at
University of Pittsburgh Medical Center (UPMC) e Shadyside
campus between July 2000 and October 2006. All patients
were treated by one interventionist (MHW). Patients
included in the study underwent CAS protected with a DPF
and had 30-day follow-up data available on their records,
which included but was not limited to the occurrence of
myocardial infarct (MI), TIA, stroke, or death due to any
cause within 30 days of the procedure. Additional inclusion
and exclusion criteria were based upon the specific trial inwhich each patient was enrolled, including SAPPHIRE,25
ARCHeR,26 BEACH,27 CABERNET,28 and CREST.29 There was
overlap in the inclusion and exclusion criteria among these
trials. General inclusion criteria included age greater than
18 years, symptomatic stenosis greater than 50%, asymp-
tomatic stenosis greater than 70% (CREST) or 80%, and at
least one high-risk criterion (high-risk trials). Typical
exclusion criteria included total ipsilateral occlusion,
recent stroke, and known source of cardiac emboli.
Baseline characteristics were collected for each patient,
including age, sex, cardiovascular risk factors, history of
cardiovascular disease, and medical history. Please refer to
Table 1 for a complete list of variables examined in the study.
DPF design characteristics, including capture efficiency,
vascular resistance, porosity, pore density, eccentricity,
and wall apposition, were measured previously.24,30,31 The
capture efficiency of each DPF was measured in a bench-top
flow apparatus where 5 mg of microspheres were injected
into the system, simulating plaque embolization.30 The ideal
capture efficiency was 100%. Vascular resistance was calcu-
lated as the ratio of the pressure gradient across the distal
protection filter to the flow rate in the flowmodel.30 Porosity
and pore density were calculated using images captured by
a CCD camera mounted on a microscope.24 Porosity was
defined as the ratio of porous surface area to total surface
area, while pore density was defined as the ratio of number of
pores to total surface area. Wall apposition was quantified
using photographs of the DPF in the coronal plane; the ideal
wall apposition was 0%, where there are no gaps between the
DPF and the vessel wall.31
Generally, the CAS procedures followed a similar
protocol: patients were treated with aspirin prior to the
procedure and continued indefinitely. They received clo-
pidogrel 24 h before the procedure and for 3e4 months
following the procedure. Nearly all patients received
bivalirudin unless they arrived to the angiography suite on
unfractionated heparin, in which case, heparin was the anti-
coagulant, maintaining an activated partial-thromboplastin
time of 250e300 s. Access was gained through the common
femoral artery. The lesionwas crossedwith theDPF guidewire
and expanded. After the stent was deployed, it was post-
dilated and the filter collapsed and removed.Statistical Analysis
Univariate analysis was used to quantify the association
between each binary clinical variable and each individual
outcome (TIA, stroke, neurologic-related death, after
30-days) and composite adverse event outcome (occur-
rence of any individual outcome) at a significance level of
aZ .05 using SAS v9.2 (SAS Institute Inc., Cary, NC). The p-
value, odds ratio (OR), and 95% confidence interval (CI)
were reported for each clinical variable. Subgroup analysis
of symptomatic status and octogenarians were also con-
ducted. Significant variables found in univariate analysis
were used for multivariate analysis, although, in general,
the consensus is that 10 subjects are required for each
covariate; thus, at most 2 covariates could be examined
simultaneously.32 After variable selection, the importance
of each variable was assessed by a Wald statistic value
greater than 2, which is approximately an a Z .05
Table 1 Patient characteristics and their p-value, odds ratio, and 95% confidence interval.
Characteristic Number
(Percentage)
TIA
p-value
OR (95% CI)
Stroke
p-value
OR (95% CI)
Death
p-value
OR (95% CI)
Adverse Event
p-value
OR (95% CI)
Age > 80 years 33 (16.1) .96 .85 .09 .61
n/a 1.2 (.2e5.7) 5.5 (.7e40.4) .7 (.1e3.1)
Male 137 (66.8) .58 .38 .96 .47
.7 (.1e3.0) .6 (.2e2.0) n/a .7 (.2e1.9)
Diabetes mellitus 63 (30.7) .14 .28 .41 .04
3.1 (.7e14.5) 2.0 (.6e6.7) 2.3 (.3e16.7) 2.8 (1.0e7.6)
History of dyslipidemia 143 (69.8) .92 .65 .82 .64
1.1 (.2e5.8) .7 (.2e2.6) 1.3 (.1e12.8) .8 (.3e2.2)
History of hypertension 159 (77.6) .95 .07 .21 .47
n/a .3 (.1e1.1) .3 (0e2.0) .7 (.2e2.0)
Current smoking 36 (17.6) .44 .39 .70 .19
1.9 (.4e10.4) 1.8 (.5e7.3) 1.6 (.2e15.6) 2.1 (.7e6.4)
Atrial fibrillation 26 (12.7) .97 .71 .47 .39
n/a .7 (.1e5.5) 2.3 (.2e23.4) .4 (.1e3.2)
Prior CEA 84 (41.0) .07 .04 .31 .03
2.0 (.9e4.4) 2.0 (1.0e3.7) 1.7 (.6e4.8) 1.8 (1.1e3.1)
Restenosis after CEA 52 (25.4) .85 .29 .98 .26
1.2 (.2e6.3) 2.0 (.5e7.5) 1.0 (.1e9.6) 1.9 (.6e5.4)
CHF 39 (19.0) .52 .48 .76 .26
1.7 (.3e9.3) 1.6 (.4e6.5) 1.4 (.1e14.1) 1.9 (.6e5.7)
Prior MI 54 (26.3) .47 .94 .30 .78
.5 (.1e3.9) 1.1 (.3e4.1) 2.9 (.4e20.9) .8 (.3e2.7)
Prior CABG 82 (40.0) .20 .71 .69 .69
.2 (0e2.1) 1.3 (.4e4.1) 1.5 (.2e10.0) .8 (.3e2.2)
Prior TIA 69 (33.7) .67 .88 .76 .91
1.3 (.4e3.9) 1.1 (.4e3.0) .7 (.1e5.7) 1.0 (.5e2.4)
Prior stroke 50 (24.4) .54 .01 .26 .11
.5 (.1e4.3) 5.0 (1.6e15.9) 2.8 (.5e17.6) 2.2 (.8e5.8)
PVD 44 (21.5) .64 .06 .19 .15
.6 (.1e5.1) 3.3 (1.0e11.4) 3.8 (.5e27.7) 2.2 (.7e6.2)
CAD 120 (58.5) .40 .33 .51 .59
.5 (.1e2.4) 2.0 (.5e7.6) 2.2 (.2e21.1) 1.3 (.5e3.7)
ESRD 8 (3.9) .98 .38 .98 .66
n/a 2.7 (.3e23.9) n/a 1.6 (.2e14.0)
COPD 33 (16.1) .89 .31 .63 .39
.9 (.1e7.4) 2.1 (.5e8.2) 1.8 (.2e17.5) 1.7 (.5e5.5)
Contralateral occlusion 39 (19.0) .75 .40 .76 .43
.7 (.1e6.0) .4 (.1e3.3) 1.4 (.1e14.1) .5 (.1e2.5)
Asymptomatic 139 (67.8) .83 .34 .45 .41
1.2 (.2e6.3) .6 (.2e1.9) .5 (.1e3.4) .7 (.2e1.8)
Close cell stent 49 (23.9%) .05 .79 .96 .26
4.5 (1.0e21.0) 1.2 (.3e4.7) n/a 1.8 (.6e5.3)
n/aZ not applicable (patient did not have characteristic and outcome in question), TIAZ transient ischemic attack, ORZ odds ratio,
CI Z confidence interval, CHF Z congestive heart failure, CABG Z coronary artery bypass graft, PVD Z peripheral vascular disease,
CAD Z coronary artery disease, ESRD Z end stage renal disease, COPD Z chronic obstructive pulmonary disease.
284 G.M. Siewiorek et al.significance level. The fit of the model was assessed with
the Hosmer and Lemeshow Goodness-of-Fit test,32 where
a p-value less than .05 indicated an ill-fit model.
Univariate analysis was also conducted for the DPF
characteristics. Each DPF characteristic except concen-
tricity was assumed a continuous variable taking the values
given in Table 2. The rationale behind treating these vari-
ables as continuous is that it accounts for patient-to-patient variability for wall apposition, capture efficiency,
and vascular resistance. It also accounts for variability in
filter-to-filter manufacturing concerning porosity and pore
density. Similar to the clinical variables, the association
between each covariate and outcome was examined. The
association between each variable (both clinical and DPF)
was quantified for each TIA, stroke, neurologic-related
death, and adverse event after 30 days.
Table 2 DPFa design characteristics.26,31,32
DPF Accunet Angioguard FilterWire Emboshield Spider
Capture efficiencyb 95.1 63.7 96.1 64.6 99.9
Vascular resistancec 24.8 30.6 12.8 14.7 3.5
Porosityd 4.5 11.3 12.9 2.2 50.4
Number of pores 912 1100 2576 400 1563
Pore densitye 4.4 14.4 13.6 1.4 10
Wall appositionf .075 4.2 .65 0 .49
Concentric 1 1 0 1 0
a DPF Z distal protection filter.
b Capture efficiency Z percentage of emboli captured by DPF.
c Vascular resistance measurements are expressed as a ratio of the vascular resistance in the ICA at full filter conditions normalized to
the initial condition.
d Porosity is percentage of porous surface area to total surface area of DPF basket.
e Pore density is ratio of total number of pores to total surface area DPF basket.
f Wall apposition represented by a gap between the device and the arterial wall, expressed as a % of vessel cross-sectional area at the
site of device deployment.
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The information from 208 procedures performed on 206
patients was collected for statistical analysis. Of the 208
patients included in the study, there were 2 MIs, 7 TIAs, 12
strokes, and 6 deaths in 20 patients. The 30-day all-cause
stroke and death rate was 8.7% (12 strokes, 6 deaths: 18
events/208 patients). For asymptomatic patients, the 30-
day all-cause stroke and death rate was 7.7% (7 strokes, 4
deaths: 11 events/142 patients), while for symptomatic
patients it was 10.6% (5 strokes, 2 deaths: 7 events/66
patients). Five patients had a stroke and died within 30
days. The sixth patient died from a non-neurologic cause
and was excluded from the analysis. Due to the low number
of MI, it was also excluded from the analysis. In the final
data set (i.e., excluding non-neurologic deaths and MI), the
average age was 72-years  9 and almost two-thirds of
the patients were male (66.8%) and asymptomatic (67.8%).
The baseline characteristics are shown in Table 1. The 30-
day stroke and neurologic death rate was 7.3% (11 strokes,
4 deaths: 15 events/205 patients). For asymptomatic
patients, the 30-day stroke and neurologic death rate was
5.8% (6 strokes, 2 deaths: 8 events/139 patients), and for
symptomatic patients it was 10.6% (5 strokes, 2 deaths: 7
events/66 patients). These stroke and death rates were
higher than the American Heart Association (AHA) guide-
lines for carotid interventions (3% for asymptomatic
patients; 6% for symptomatic patients).33
There were five different DPFs used in the 208 patients:
Accunet, Angioguard, FilterWire, Emboshield, and Spider.Table 3 DPF distribution.
DPF Number (Percentage) TIA
RX Accunet 86 (41.3) 2
Angioguard 69 (33.2) 1
FilterWire 50 (24.0) 4
Emboshield 2 (1.0) 0
Spider RX 1 (.5) 0
DPF Z distal protection filter, TIA Z transient ischemic attack.Table 3 gives the distribution of the DPFs used during CAS.
Due to the low number of patients treated with Emboshield
(nZ 2) and Spider (nZ 1), theywereexcluded from thefilter
analysis. In addition, Emboshield nowhas an updated design,
Emboshield NAV6, further justifying its removal from the
statistical treatment of the data. The earliest cases used
Angioguard as this was the only DPF available at the time.
With few exceptions, nearly all patients were treated with
the manufacturer’s recommended DPF-stent pair.
Univariate analysis yielded several variables that
reached significance (see Table 1). Noteworthy are diabetes
mellitus (P Z .04, OR: 2.8, CI: 1.0e7.6) and prior CEA
(P Z .03, OR: 1.8, CI: 1.1e3.1) were significantly associ-
ated with adverse event. Peri-procedural stroke was
significantly associated with prior CEA (PZ .04, OR: 2.0, CI:
1.0e3.7) and prior stroke (PZ .01, OR: 5.0, CI: 1.6e15.9),
while peri-procedural TIA was significantly associated with
closed-cell stents (P Z .05, OR: 4.5, CI: 1.0e21.0).
Multivariate models were created with variables having
a Wald statistic greater than 2 and non-significant Good-
ness-of-Fit p-value. Two models were created: adverse
event within 30 days of CAS was associated with diabetes
melliutus and prior CEA, while stroke within 30 days of CAS
was associated with both prior stroke and CEA.
Subgroup analysis did not yield many statistically signifi-
cant results, as shown in Tables 4 and 5. Asymptomatic
patients with prior CEA were significantly associated with
adverse events (P Z .04, OR: 2.0, CI: 1.0e3.8) and symp-
tomatic patients who had prior stroke were significantly
associated with peri-procedural stroke (P Z .04, OR: 11.3,Stroke Death Adverse event
4 1 7
5 4 6
3 0 6
0 1 1
0 0 0
Table 4 Asymptomatic patient characteristics and their p-value, odds ratio, and 95% confidence interval.
Characteristic TIA
p-value
OR (95% CI)
Stroke
p-value
OR (95% CI)
Death
p-value
OR (95% CI)
Adverse Event
p-value
OR (95% CI)
Asymptomatic Symptomatic Asymptomatic Symptomatic Asymptomatic Symptomatic Asymptomatic Symptomatic
Age > 80 years .97 .97 .91 .91 .22 .28 .64 .78
n/a n/a 1.1 (.1e10.2) 1.1 (.1e11.2) 5.9 (.4e97.4) 4.8 (.3e83.0) .6 (.1e5.0) .7 (.1e6.7)
Male .16 .95 .29 .98 .96 .95 .17 .54
.3 (0e1.7) n/a .4 (.1e2.1) 1.0 (.2e6.3) n/a n/a .4 (.1e1.5) 1.7 (.3e9.6)
Diabetes mellitus .19 .52 .93 .13 .58 .52 .21 .10
3.4 (.5e21.1) 2.6 (.2e43.1) 1.1 (.2e6.1) 4.2 (.6e27.6) 2.2 (.1e35.8) 2.6 (.2e43.1) 2.3 (.6e8.4) 3.9 (.8e19.5)
History of dyslipidemia .73 .72 .70 .92 .96 .72 .80 .77
1.5 (.2e13.6) .6 (0e10.0) .7 (.1e4.1) .9 (.1e5.8) n/a .6 (0e10.0) .8 (.2e3.4) .8 (.2e3.9)
History of hypertension .96 .96 .08 .51 .33 .48 .43 .94
n/a n/a .2 (0e1.2) .5 (.1e3.5) .2 (0e4.1) .4 (0e6.1) .6 (.1e2.3) .9 (.2e5.3)
Current smoking .16 .96 .95 .30 .97 .35 .22 .62
3.8 (.6e24.2) n/a 1.1 (.1e9.6) 2.7 (.4e18.2) n/a 3.9 (.2e67.0) 2.5 .6e10.4) 1.6 (.3e9.1)
Atrial fibrillation .97 .97 .97 .67 .97 .18 .96 .96
n/a n/a n/a 1.7 (.2e16.8) n/a 7.0 (.4e123.4) n/a 1.1 (.1e10.0)
Prior CEA .06 .95 .06 .27 .55 .29 .04 .32
2.3 (1.0e5.6) 1.1 (.1e8.1) 2.2 (1.0e5.0) 1.9 (.6e6.2) 1.5 (.4e6.3) 2.6 (.4e14.7) 2.0 (1.0e3.8) 1.7 (.6e4.7)
Restenosis after CEA .58 .97 .26 .73 .52 .97 .14 .91
1.7 (.3e10.5) n/a 2.6 (.5e13.4) 1.5 (.1e16.0) 2.5 (.2e41.2) n/a 2.7 .7e9.8) .9 (.1e8.2)
CHF .87 .38 .97 .35 .26 .96 .81 .19
1.2 (.1e11.3) 3.6 (.2e60.8) 1.0 (.1e8.6) 2.5 (.4e16.3) 5.0 (.3e82.2) n/a 1.2 (.2e6.1) 2.9 (.6e14.9)
Prior MI .66 .96 .26 .96 .95 .96 .42 .96
.6 (.1e5.6) n/a 2.6 (.5e13.4) n/a n/a n/a 1.7 (.5e6.5) n/a
Prior CABG .35 .95 .70 .33 .80 .74 .47 .79
.3 (0e3.2) n/a .7 (.1e4.0) 2.2 (.4e11.4) 1.4 (.1e23.6) 1.5 (.1e19.7) .6 (.1e2.4) 1.2 (.3e5.4)
Prior TIA .29 .84 .38 .23 .98 .32 .72 .39
3.5 (.4e34.4) 1.2 (.2e8.3) 2.8 (.3e26.2) .3 (.1e2.0) n/a .2 (0e3.9) 1.5 (.2e13.0) .5 (.1e2.3)
Prior stroke .93 .96 .12 .04 .37 .55 .53 .19
.9 (.1e7.8) n/a 3.2 (.7e14.1) 11.3 (1.2e108.3) 3.0 (.3e34.9) 2.4 (.1e39.9) 1.5 (.4e5.8) 3.6 (.7e17.8)
PVD .93 .96 .11 .30 .36 .35 .15 .62
.9 (.1e8.4) n/a 3.9 (.8e20.5) 2.7 (.4e18.2) 3.7 (.2e61.4) 3.9 (.2e67.0) 2.6 (.7e10.1) 1.6 (.3e9.1)
CAD .96 .94 .78 .24 .95 .93 .55 .82
1.0 (.2e5.9) n/a 1.3 (.2e7.3) 3.9 (.4e36.7) n/a .9 (.1e14.7) 1.5 (.4e6.2) .2 (.2e5.9)
ESRD .98 .99 .98 .07 .98 .99 .98 .12
n/a n/a n/a 15.0 (.8e286.8) n/a n/a n/a 9.7 (.5e175.1)
COPD .80 .97 .95 .17 .97 .25 .71 .38
1.3 (.1e12.6) n/a 1.1 (.1e9.6) 3.9 (.6e26.4) n/a 5.4 (.3e93.6) 1.4 (.3e6.9) 2.2 (.4e13.3)
Contralateral occlusion .97 .35 .93 .96 .28 .96 .50 .64
n/a 3.9 (.2e67.0) .9 (.1e8.1) n/a 4.7 (.3e77.9) n/a .5 (.1e4.0) .6 (.1e5.3)
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Clinical Variables, DPFs, and CAS 287CI: 1.2e108.3). Unexpectedly, patients with prior stroke
were significantly associated with peri-procedural stroke,
even though they were less than 80-years old (PZ .01, OR:
7.3, CI: 1.7e30.5). Results for octogenarians were the same
since one patient experienced stroke and death; there were
no TIAs amongst octogenarians.
The DPF design characteristics analysis revealed some
remarkable results (see Table 6). Neurologic death within
30 days of CAS was significantly associated with capture
efficiency (P Z .004), vascular resistance (P Z .04), and
wall apposition (P Z .004). TIA within 30 days of CAS was
significantly associated with vascular resistance (P Z .04)
and number of pores (P Z .046). A second analysis that
quantified the association between the DPF itself and
outcome did not yield significant results.Discussion
The statistically significant clinical variables obtained in
the present investigation corroborate findings of previous
studies. Recently, the results of the CREST (Carotid
Revascularization Endarterectomy vs. Stenting Trial) were
published, which randomized conventional risk patients 1:1
to surgical or endovascular treatment.34 In this study, 96.1%
of patients had embolic protection. Although there was no
difference between CEA and CAS in the primary end point
of MI, stroke, or death from any cause during the peri-
procedural period or any ipsilateral stroke within 4 years
after randomization (P Z .51),34 the CREST authors indi-
cated that CAS is more effective in younger patients.29,34
Although our study did not find a significant relationship
between age and any of the outcomes investigated,
younger patients with prior stroke were more likely to have
a stroke within 30 days of CAS. Diabetes was also found
significantly associated with adverse outcomes.4,8 Previ-
ously, Malik et al. found an association between restenosis
after CEA and minimal emboli generation, suggesting that
cerebral protection may not be necessary for this subset of
patients.15 Touze´ et al. found that patients who had carotid
restenosis after CEA and treated with the use of a CPD had
lower risk of stroke and death.10 However, our investigation
found a significant association between prior CEA patients
and peri-procedural stroke and adverse events. Subgroup
analysis indicated that patients who had prior stroke are at
higher risk of having a stroke within 30 days of CAS, espe-
cially symptomatic patients and, surprisingly, patients less
than 80-years old.
Although not statistically significant, peripheral vascular
disease had an elevated OR for peri-procedural stroke (OR:
3.3, CI: 1.0e11.4). Elevated OR were found for asymp-
tomatic patients with prior CEA who underwent
peri-procedural TIA (PZ .06, OR: 2.3, CI: 1.0e5.6) or peri-
procedural stroke (P Z .06, OR: 2.2, CI: 1.0e5.0). Closed
cell stents also had an elevated OR for peri-procedural TIA
in younger patients (P Z .06, OR: 4.5, CI: 1.0e20.8).
This work advances previous statistical studies by the
inclusion of DPF-specific design characteristics. Similar to
previous studies that have quantified stent design param-
eters,17e21 DPF design characteristics were quantified and
postulated to have an effect on CAS outcome. To this end,
numerous studies have used logistic regression to predict
Table 5 Octogenarian patient characteristics and their p-value, odds ratio, and 95% confidence interval.
Characteristic TIA
p-value
OR (95% CI)
Stroke
p-value
OR (95% CI)
Death
p-value
OR (95% CI)
Adverse Event
p-value
OR (95% CI)
Octogenarian Age < 80 Octogenarian Age < 80 Octogenarian Age < 80 Octogenarian Age < 80
Male n/a .58 .95 .16 .95 .95 .95 .25
n/a .6 (.1e3.0) n/a .4 (.1e1.5) n/a n/a n/a .5 (.2e1.6)
Diabetes mellitus n/a .15 .47 .39 .47 .58 .47 .06
n/a 3.0 (.7e14.2) 2.9 (.2e51.5) 1.8 (.5e7.0) 2.9 (.2e51.5) 2.2 (.1e36.0) 2.9 (.2e51.5) 2.8 (.9e8.0)
History of dyslipidemia n/a .996 .95 .29 .95 .51 .95 .31
n/a 1.0 (.2e5.3) n/a .5 (.1e1.9) n/a .4 (0e6.4) n/a .6 (.2e1.7)
History of hypertension n/a .95 .34 .12 .34 .38 .34 .70
n/a n/a .2 (0e4.4) .3 (.1e1.3) .2 (0e4.4) .3 (0e4.7) .2 (0e4.4) .8 (.2e2.6)
Current smoking n/a .58 .99 .33 .99 .33 .99 .20
n/a 1.6 (.3e8.6) n/a 2.0 (.5e8.6) n/a 4.0 (.2e65.6) n/a 2.1 (.7e6.7)
Atrial fibrillation n/a .97 .34 .96 .34 .97 .34 .97
n/a n/a 4.2 (.2e76.6) n/a 4.2 (.2e76.6) n/a 4.2 (.2e76.6) n/a
Prior CEA n/a .10 .92 .32 .92 .93 .92 .23
n/a 1.9 (.9e4.1) n/a 1.4 (.7e3.0) n/a n/a n/a 1.4 (.8e2.5)
Restenosis after CEA n/a .92 .27 .49 .27 .96 .27 .44
n/a 1.1 (.2e5.8) 5.2 (.3e97.6) 1.7 (.4e7.3) 5.2 (.3e97.6) n/a 5.2 (.3e97.6) 1.6 (.5e5.0)
CHF n/a .32 .75 .54 .75 .97 .75 .20
n/a 2.4 (.4e12.8) 1.6 (.1e27.8) 1.7 (.3e8.4) 1.6 (.1e27.8) n/a 1.6 (.1e27.8) 2.2 (.7e7.6)
Prior MI n/a .62 .96 .99 .96 .37 .96 .84
n/a .6 (.1e4.9) 1.1 (.1e18.6) 1.0 (.2e5.1) 1.1 (.1e18.6) 3.6 (.2e58.9) 1.1 (.1e18.6) .9 (.2e3.3)
Prior CABG n/a .23 .91 .65 .91 .71 .91 .75
n/a .3 (0e2.3) .9 (.1e11.7) 1.4 (.4e5.3) .9 (.1e11.7) 1.7 (.1e27.6) .9 (.1e11.7) .8 (.3e2.5)
Prior TIA n/a .62 .84 .95 .84 .95 .84 .93
n/a 1.3 (.4e3.9) 1.3 (.1e15.3) 1.0 (.3e3.2) 1.3 (.1e15.3) n/a 1.3 (.1e15.3) 1.0 (.4e2.5)
Prior stroke n/a .55 .53 .01 .53 .41 .53 .14
n/a .5 (.1e4.4) 2.1 (.2e19.9) 7.3 (1.7e30.5) 2.1 (.2e19.9) 3.2 (.2e52.7) 2.1 (.2e19.9) 2.3 (.8e6.9)
PVD n/a .62 .27 .11 .27 .37 .27 .28
n/a .6 (.1e4.9) 5.2 (.3e97.6) 3.0 (.8e11.9) 5.2 (.3e97.6) 3.6 (.2e58.9) 5.2 (.3e97.6) 1.9 (.6e5.9)
CAD n/a .45 .95 .55 .95 .84 .95 .80
n/a .6 (.1e2.5) n/a 1.5 (.4e6.4) n/a .8 (0e12.2) n/a 1.1 (.4e3.4)
ESRD n/a .98 n/a .36 n/a .98 n/a .70
n/a n/a n/a 2.8 (.3e25.5) n/a n/a n/a 1.5 (.2e13.3)
COPD n/a .82 .98 .21 .98 .27 .98 .33
n/a .8 (.1e6.7) n/a 2.5 (.6e10.7) n/a 4.9 (.3e80.0) n/a 1.8 (.5e6.2)
Contralateral occlusion n/a .92 .68 .96 .68 .97 .68 .33
n/a .9 (.1e7.7) 1.8 (.1e32.0) n/a 1.8 (.1e32.0) n/a 1.8 (.1e32.0) .4 (0e2.9)
Asymptomatic n/a .87 .68 .39 .68 .58 .68 .45
n/a 1.2 (.2e6.1) .6 (0e9.7) .6 (.1e2.1) .6 (0e9.7) .5 (0e7.4) .6 (0e9.7) .7 (.2e2.0)
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Clinical Variables, DPFs, and CAS 289patient outcome following CAS. Iyer et al. reviewed retro-
spectively 3160 protected CAS cases treated with nine
different CPDs.23 Eccentric filters (FilterWire, Spider) were
used in 60.4% of procedures, concentric filters (Emboshield,
Angioguard, Trap, Accunet) were used in 32.4%, and the
rest used balloon devices. There was no statistically
significant difference in the risk for having a procedural
adverse event as compared to FilterWire, the most
frequently used device. However, there was an increased
30-day adverse event rate for Accunet as compared to Fil-
terWire (P Z .05). Pairwise comparisons of device type
revealed that there was no significant difference in the risk
of having an adverse event 30-days post-procedure. There
was an increased risk for eccentric filters over concentric
filters (P Z .04), however, when adjusting for risk factors
and stent type, there was no difference.
One recent study attempted to differentiate patient
outcome based on DPF used.22 The analysis used clinical
data and was based upon peri-procedural flow impairment
of three DPFs (Angioguard, FilterWire, Spider). Flow
obstruction occurred more frequently with the use of
Angioguard over FilterWire and Spider. All the procedures
experiencing no flow occurred with Angioguard. Elevated
odds ratio was found for open-cell stent designs and
concentric DPFs.2 The authors concluded that further
analysis of device design variables needs to be investigated;
in particular for symptomatic patients or those with echo-
lucent lesions, the use of closed-cell stents and eccentric
CPDs may be warranted. It is important to note that anal-
ysis of binary attributes such as open- or closed-cell stents
or one-dimensional measures such as cell size can be
misleading due to unaccounted for design characteristics.19
The assessment of DPF design characteristics and patient
outcome in this work revealed that capture efficiency had
a significant association with patient outcome after 30 days.
Having a high capture efficiency being beneficial for patient
outcome is intuitive; it is likely that less debris travels to the
intracranial circulation and causes a neurologic event. A high
vascular resistance indicates decreased blood flow to the
brain, which can result in a neurologic occurrence. The
number of pores is another indicator of the amount of blood
flow; the more pores, the more blood reaches the brain
through the ICA. Poor wall apposition can have a negative
effect on patients due to plaque emboli potentially occur-
ring between the DPF and the artery wall downstream.
Concentricity was not found to be significantly associated
with any of the outcomes. This finding disagrees with the
work of Hart et al. in which eccentric filters were considered
superior to concentric filters2 but agrees with Iyer et al. in
which there was no statistical difference between eccentric
and concentric filters.23 In addition, vascular resistance and
number of pores had an indeterminate effect on patient
outcome. Porosity and pore density were not significant,
although these measures have an effect on vascular resis-
tance, which was positively associated with procedural
death. Thus, our hypothesis proved to be partially true; high
capture efficiency DPFs are beneficial for patient outcome,
while parameters quantifying the effect of a DPF on local
blood flow conditions have an indeterminate or negative
effect.
Due to one DPF used more than others during consecu-
tive periods, operator experience could play a role, with
Table 6 DPF design characteristics and statistical significance (P < .05).
Design Characteristic TIA Stroke Death Adverse Event
Capture Efficiency .24 .42 .004 .93
Vascular Resistance .04 .86 .04 .44
Porosity .31 .36 .19 .25
Number of Pores .046 .74 .40 .26
Pore Density .56 .32 .06 .31
Wall Apposition .37 .37 .004 .79
Concentric .06 .83 .96 .29
OR (95% CI) .2 (.1e1.1) .9 (.2e3.4) n/a .6 (.2e1.6)
DPF Z distal protection filter, OR Z odds ratio, CI Z confidence interval.
290 G.M. Siewiorek et al.more favorable results occurring the more the device was
used. However, since an experienced interventionist with
20þ years of experience treated all patients, the operator
effect should be minimal. Furthermore, as Iyer noted,23
adjusting for stent type for each DPF can change the rela-
tive risk of procedural adverse events. Since nearly all cases
used the manufacturer’s recommended stent-DPF pair,
such analysis would not be useful.
There are several limitations associated with the current
investigation. It is important to note that the calculated
associations quantify a measure of probability that the
outcome will occur; it does not give a direct cause-and-
effect relationship. Associations between variables can be
found although they may not make clinical sense. Thus,
predictions made by these statistic analyses need to be
interpreted with care. This study was a retrospective
analysis based on existing medical records, which were
recorded for reasons other than research. For this reason, it
is possible that a retrospective study will miss important
contributing factors. However, hypotheses can be gener-
ated for future, prospective studies to investigate further
cause-and-effect relationships. In addition, patients inc-
luded in this study were treated at a single center (UPMC).
A multiple center study would be more representative of
the overall CAS patient population due to exclusion of
systematic reporting biases or policies on patient treat-
ment. Finally, this study should benefit from the inclusion
of more patient data; if the patient population is large
enough, a multivariate logistic regression equation can be
derived. The size of the patient population is dependent
upon the number of covariates examined simultaneously.32
Assuming a 3% or 6% adverse event rate (AHA’s target stroke
and death rate for asymptomatic and symptomatic patients
undergoing repair, respectively)33 and three simultaneous
covariates, the patient population should be between 500
and 1000 subjects. A multivariate logistic regression equa-
tion has the advantage of examining multiple variables
simultaneously and quantifying interactions between vari-
ables (e.g., the relationship between hypertension, current
smoking, and dyslipidemia).
Conclusion
A retrospective analysis of clinical variables can provide
valuable information for rigorous patient selection that can
yield a favorable CAS outcome. This study serves as
a preliminary investigation to determine factors that areinfluential on patient outcome. Future studies with a larger
sample size will yield more statistically significant results,
particularly to assess theeffect of DPF design characteristics.
Design parameters that correlate with adverse outcomes can
be avoided in designs of future device generations.
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